This article needs additional citations for verification. (May 2016) |
Names | |
---|---|
Preferred IUPAC name
4-(2-Aminoethyl)benzene-1-sulfonyl fluoride | |
Other names
Pefabloc SC
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
MeSH | AEBSF |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C8H10FNO2S.HCl | |
Molar mass | 239.69 g/mol |
200 mg/mL[1] | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
AEBSF or 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride is a water-soluble, irreversible serine protease inhibitor with a molecular weight of 239.5 Da. It inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin. The specificity is similar to the inhibitor PMSF, nevertheless AEBSF is more stable at low pH values. Typical usage is 0.1 - 1.0 mM. AEBSF (marketed as Pefabloc SC from the company Pentapharm) was first reported for use in biochemistry in 1993, and came into common use for the inhibition serine proteases and of non-protease enzymes such as acetylhydrolases in the mid 1990s.[2]